Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,276
archived clinical trials in
Pancreatic Cancer

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Banner Healthcare
mi
from
Gilbert, AZ
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Banner Healthcare
mi
from
Gilbert, AZ
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Scottsdale Healthcare
mi
from
Scottsdale, AZ
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Christiana Care Health Services Helen Graham Cancer Center
mi
from
Newark, DE
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Christiana Care Health Services Helen Graham Cancer Center
mi
from
Newark, DE
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Jackson North Medical Center
mi
from
Miami, FL
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Jackson North Medical Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Sylvester Comprehensive Cancer Center Univ. Miami
mi
from
Miami, FL
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Sylvester Comprehensive Cancer Center Univ. Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Moffitt Cancer Center
mi
from
Tampa, FL
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Winship Cancer Institute
mi
from
Atlanta, GA
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Mountain States Tumor Institute
mi
from
Boise City, ID
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Mountain States Tumor Institute
mi
from
Boise City, ID
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Goshen Center for Cancer Care
mi
from
Goshen, IN
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Goshen Center for Cancer Care
mi
from
Goshen, IN
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Detroit Clinical Research Center
mi
from
Novi, MI
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Detroit Clinical Research Center
mi
from
Novi, MI
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
St. Mary's Trinity Healthcare
mi
from
Grand Rapids, MI
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
St. Mary's Trinity Healthcare
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
New Mexico Cancer Care Alliance
mi
from
Albuquerque, NM
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
New Mexico Cancer Care Alliance
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Weill Cornell NY Presbyterian Hospital
mi
from
New York, NY
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Weill Cornell NY Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Mt. Sinai Medical Center
mi
from
New York, NY
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Mt. Sinai Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
University of North Carolina Medical Center
mi
from
Chapel Hill, NC
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
University of North Carolina Medical Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Kimmel Cancer Center at Jefferson University
mi
from
Philadelphia, PA
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Kimmel Cancer Center at Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Hillman Cancer Center
mi
from
Pittsburgh, PA
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Institute for Translational Oncology Research
mi
from
Greenville, SC
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Institute for Translational Oncology Research
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Tyler Cancer Center
mi
from
Tyler, TX
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
VA Oncology Associates
mi
from
Norfolk, VA
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
VA Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated:  9/24/2012
Virginia Mason Medical Center
mi
from
Seattle, WA
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status: Enrolling
Updated: 9/24/2012
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
Status: Enrolling
Updated:  10/12/2012
University of Kansas Medical Center Cancer Center
mi
from
Kansas City, KA
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
Status: Enrolling
Updated: 10/12/2012
University of Kansas Medical Center Cancer Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
Phase I Trial of Chemoradiation With Capecitabine and Vorinostat in Pancreatic Cancer.
Status: Enrolling
Updated:  11/2/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
Phase I Trial of Chemoradiation With Capecitabine and Vorinostat in Pancreatic Cancer.
Status: Enrolling
Updated: 11/2/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Pilot Study to Assess Safety and Efficacy of an Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Status: Enrolling
Updated:  12/18/2012
Weill Medical College of Cornell University
mi
from
New York, NY
Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Pilot Study to Assess Safety and Efficacy of an Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Status: Enrolling
Updated: 12/18/2012
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer
Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer
Status: Enrolling
Updated:  1/4/2013
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer
Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer
Status: Enrolling
Updated: 1/4/2013
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated:  2/27/2013
Stephenson Cancer Center
mi
from
Oklahoma City, OK
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated: 2/27/2013
Stephenson Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Studying Biomarkers in Patients With Pancreatic Cancer
Developing Biomarkers in Pancreatic Cancer
Status: Enrolling
Updated:  3/2/2013
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Studying Biomarkers in Patients With Pancreatic Cancer
Developing Biomarkers in Pancreatic Cancer
Status: Enrolling
Updated: 3/2/2013
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Click here to add this to my saved trials
Studying Biomarkers in Patients With Pancreatic Cancer
Developing Biomarkers in Pancreatic Cancer
Status: Enrolling
Updated:  3/2/2013
Vanderbilt-Ingram Cancer Center at Franklin
mi
from
Nashville, TN
Studying Biomarkers in Patients With Pancreatic Cancer
Developing Biomarkers in Pancreatic Cancer
Status: Enrolling
Updated: 3/2/2013
Vanderbilt-Ingram Cancer Center at Franklin
mi
from
Nashville, TN
Click here to add this to my saved trials
Studying Biomarkers in Patients With Pancreatic Cancer
Developing Biomarkers in Pancreatic Cancer
Status: Enrolling
Updated:  3/2/2013
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Studying Biomarkers in Patients With Pancreatic Cancer
Developing Biomarkers in Pancreatic Cancer
Status: Enrolling
Updated: 3/2/2013
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Birmingham Hematology and Oncology Associates, LLC
mi
from
Birmingham, AL
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Birmingham Hematology and Oncology Associates, LLC
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
California Cancer Associates for Research and Excellence (CCARE)
mi
from
Fresno, CA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
California Cancer Associates for Research and Excellence (CCARE)
mi
from
Fresno, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Pacific Shores Medical Group
mi
from
Long Beach, CA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Pacific Shores Medical Group
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
UCLA Community Oncology Practice
mi
from
Los Angeles, CA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
UCLA Community Oncology Practice
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Hematology-Oncology Medical Group of Orange County, Inc.
mi
from
Orange, CA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Hematology-Oncology Medical Group of Orange County, Inc.
mi
from
Orange, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Stanford Univ Med Ctr
mi
from
Stanford, CA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Sharp Health Care
mi
from
San Diego, CA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Sharp Health Care
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
California Pacific Medical Center
mi
from
San Francisco, CA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
San Jose Medical Group
mi
from
San Jose, CA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
San Jose Medical Group
mi
from
San Jose, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Saint Mary's Regional Cancer Center
mi
from
Grand Junction, CO
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Saint Mary's Regional Cancer Center
mi
from
Grand Junction, CO
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Hematology Oncology Associates, PC
mi
from
Stamford, CT
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Hematology Oncology Associates, PC
mi
from
Stamford, CT
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Florida Cancer Specialists
mi
from
Fort Myers, FL
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Georgia Cancer Specialists
mi
from
Atlanta, GA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Georgia Cancer Specialists
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/4/2013
Northwestern University
mi
from
Chicago, IL
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/4/2013
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials